| Autor: |
S.P. O’Malley, J.E. Sharman |
| Jazyk: |
angličtina |
| Rok vydání: |
2013 |
| Předmět: |
|
| Zdroj: |
Artery Research, Vol 7, Iss 10 (2013) |
| Druh dokumentu: |
article |
| ISSN: |
1876-4401 |
| DOI: |
10.1016/j.artres.2013.10.013 |
| Popis: |
Objectives. The BPGUIDE study was a prospective, blinded-endpoint study in 286 hypertensive patients randomised to treatment decisions guided by best-practice usual care (n = 142) or in addition by central BP measurement (n = 144; using SphygmoCor) over twelve months. This study aimed to undertake a health economic assessment to determine cost-effectiveness of hypertension management guided by central BP. Methods. The primary finding of BPGUIDE was that significantly (p < 0.001) less antihypertensive medication was used to achieve BP control in patients randomised to central BP guided care.The savings from these reductions in medications were used to determine the cost-effective fee for service and this amount was then compared to the actual financial cost of central BP measurement in order to gauge financial viability. Results. Decreases in 5 antihypertensive medication classes over time were used to calculate financial savings using the Australian Government’s Pharmaceutical Benefits Scheme dollar costs. Savings from less use of medications was calculated at $28 to $32/person (each 3 months) using a capital base cost of $10,000 (for the SphygmoCor device), 5 years capital life, 5% discount rate, patient throughput of 50/year and, labour costs up to $250/hour. Therefore, a fee for service to measure central BP of approximately $30 could be both economically and financially justifiable. Conclusions. Management of hypertension using central BP has cost-savings relating to decreased medication and may be regarded as cost-neutral when factoring in a fee for central BP measurement. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink